Latest Regulatory News

Cardiex Limited has successfully raised $2.4 million through an institutional placement to boost manufacturing and commercial activities for its CONNEQT Pulse device.

Titan Minerals Limited has launched a transaction-specific prospectus offering 4 million new options to its underwriter, exercisable at A$0.70 and expiring in January 2027. The offer, which raises no immediate funds, could inject approximately A$2.8 million upon option exercise.

Empire Energy Group has launched a $28 million equity raise to finance critical development activities in the Beetaloo Basin, targeting first gas sales from its Carpentaria Pilot Project in 2025. The capital raise, combined with a $65 million financing package, underpins the company’s ambition to commercialize one of Australia’s largest low-CO2 shale gas resources.

Spartan Resources Limited shareholders are set to vote on a scheme of arrangement for Ramelius Resources Limited to acquire all Spartan shares, creating a leading Australian gold producer with a pro forma market capitalization of $5.3 billion.

Lodestar Minerals has updated its investor presentation highlighting encouraging early drilling results from its Chilean IOCG and porphyry copper projects, alongside a clear roadmap for upcoming exploration activities.

Challenger Gold Limited’s Preliminary Feasibility Study for the Hualilan Toll Milling Project outlines a robust three-year operation delivering 450,000 tonnes of gold-silver ore to Austral Gold’s Casposo plant, with strong economics and low upfront capital.

Pursuit Minerals has withdrawn its previously stated 5,000 tonnes per annum lithium production target, clarifying it was an aspirational figure not compliant with ASX rules. The company urges investors to avoid relying on this figure for investment decisions.

Mayne Pharma has firmly rejected Cosette Pharmaceuticals’ notice attempting to terminate their merger agreement, setting the stage for a potential courtroom showdown over the disputed deal.

Battery Age Minerals Ltd (ASX, BM8) has responded to an ASX price query following a notable jump in its share price and trading volume, attributing the activity to recent public communications and exploration progress.

Xstate Resources has disposed of its 20% stake in the Austrian Anshof project, eliminating liabilities and streamlining its portfolio ahead of a planned ASX re-listing and development of its Diona project in Queensland.

Nyrada has secured ethics approval to amend its Phase I clinical trial protocol for Xolatryp, allowing testing of higher doses and extended infusion times. This strategic move aims to refine dosing ahead of Phase II trials, with final Phase I results expected by September 2025.

Elph Investments has raised and finalised its off-market takeover bid for Engenco Limited shares at $0.31 per share, applying to all shareholders including those who already accepted. This move signals a decisive step in the ongoing acquisition process.